Serina Therapeutics begins clinical trials on new Parkinson’s treatment

A Huntsville company with less than ten employees may have a new drug that could change the way Parkinson’s disease patients receive medications. HudsonAlpha associate company Serina Therapeutics has begun a clinical trial for SER-214. This drug was developed using the company’s patented polymer technology. CEO Randall Moreadith, M.D., Ph.D. explains in a segment from WAAY TV.